Synthesis and biological evaluation of imidazoquinoxalinones, imidazole analogues of pyrroloiminoquinone marine natural products

Journal of Medicinal Chemistry

Volumn 50, Issue 19, 2007, Pages 4561-4571

  Hoang, Hung ^a   LaBarbera, Daniel V ^a,b   Mohammed, Kaleem A ^b   Ireland, Chris M ^b   Skibo, Edward B ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [2 (1H INDOL 3' YL)ETHYLAMINO]4,5 DIHYDROIMIDAZO[1,5,4 DE]QUINOXALIN 9 ONE; 8 [2 (4' HYDROXYPHENYL)ETHYLAMINO]4,5 DIHYDROIMIDAZO[1,5,4 DE]QUINOXALIN 9 ONE; AMIDINE; BENZIMIDAZOLE DERIVATIVE; ETHYLENE; ETOPOSIDE; IMIDAZOLE DERIVATIVE; INDOLE; PYRROLOIMINOQUINONE DERIVATIVE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN HCT116; CONTROLLED STUDY; CULTURE MEDIUM; CYTOSTASIS; CYTOTOXICITY; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRON; HOLLOW FIBER; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE;

ACUTE TOXICITY TESTS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IMIDAZOLES; MARINE BIOLOGY; MICE; PYRROLES; QUINOLONES; QUINOXALINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34648830279     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0700870     Document Type: Article

References (35)

1. Copp, B. R.; Ireland, C. M.; Barrows, L. R. Wakayin: A novel cytotoxic pyrroloiminoquinone alkaloid from the ascidian Clavelina species. J. Org. Chem. 1991, 56 (15), 4596-4597.
2. Carney, J. R.; Scheuer, P. J.; Keliy-Borges, M. Makaluvamine G, a cytotoxic pigment from an Indonesian sponge Histodermella sp. Tetrahedron 1993, 49, 8483-8486.
3. Radisky, D. C.; Radisky, E. S.; Barrows, L. R.; Copp, B. R.; Kramer, R. A.; Ireland, C. M. Novel cytotoxic topoisomerase II inhibiting pyrroloiminoquinones from Fijian sponges of the genus Zyzzya. J. Am. Chem. Soc. 1993, 115, 1632-1638.
4. Schmidt, E. W.; Harper, M. K.; Faulkner, D. J. Makaluvamines H-M and damirone C from the Pohnpeian sponge Zyzzya fuliginosa. J. Nat. Prod. 1995, 58 (12), 1861-1867.
5. D'Ambrosio, M.; Guerriero, A.; Chiasera, G.; Pietra, F. Epinardins A-D, new pyrroloiminoquinone alkaloids of undetermined deep-water green demosponges from pre-Antarctic Indian Ocean. Tetrahedron 1996, 52 (26), 8899-8906.
6. Hooper, G. J.; Davies-Coleman, M. T.; Kelly-Borges, M.; Coetzee, P. S. New alkaloids from a South African latrunculid sponge. Tetrahedron Lett. 1996, 37 (39), 7135-7138.
7. Venables, D. A.; Concepcion, G. P.; Matsumoto, S. S.; Barrows, L. R.; Ireland, C. M. Makaluvamine N: A new pyrroloiminoquinone from Zyzzya fuliginosa. J. Nat. Prod. 1997, 60 (4), 408-410.
8. Venables, D. A.; Barrows, L. R.; Lassota, P.; Ireland, C. M. Veiutamine. A new alkaloid from the Fijian sponge Zyzzya fuliginosa. Tetrahedron Lett. 1997, 38 (5), 721-722.
9. Casapullo, A.; Cutignano, A.; Bruno, I.; Bifulco, G.; Debitus, C.; GomezPaloma, L.; Riccio, R. Makaluvamine P, a new cytotoxic pyrroloiminoquinone from Zyzzya cf. fuliginosa. J. Nat. Prod. 2001, 64 (10), 1354-1356.
10. Barrows, L. R.; Radisky, D., C.; Copp, B. R.; Swaffar, D. S.; Kramer, R. A.; Warters, R. L.; Ireland, C. M. Makaluvamines, marine natural products, are active anti-cancer agents and DNA topo II inhibitors. Anti-Cancer Drug Des. 1993, 8 (5), 333-347.
11. Islam, I.; Skibo, E. B. Synthesis and physical studies of azamitosene and iminoazamitosene reductive alkylating agents. Iminoquinone hydrolytic stability, syn/anti isomerization, and electrochemistry. J. Org. Chem. 1990, 55, 3195-3205.
12. Schulz, W. G.; Islam, E.; Skibo, E. B. Pyrrolo[1 ,2-a] benzimidazole-based quinones and iminoquinones. The role of the 3-substituent on cytotoxicity. J. Med. Chem. 1995, 38, 109-118.
13. Skibo, E. B.; Islam, I.; Schulz, W. G.; Zhou, R.; Bess, L.; Boruah, R. The organic chemistry of the pyrroio[1,2-a]benzimidazole anti-tumor agents. An example of rational drug design. Synlett 1996, 297-309.
14. Skibo, E. S.; Gordon, S.; Bess, L.; Boruah, R.; Heileman, J. Studies of pyrroio[1,2-a]benzimidazole quinone DT-diaphorase substrate activity, topoisomerase II inhibition activity, and DNA reductive aikylation. J. Med. Chem. 1997, 40, 1327-1339.
15. LaBarbera, D. V.; Skibo, E. B. Synthesis of imidazo[1,5,4-de]- quinoxalin-9-ones, benzimidazole analogues of pyrroloiminoquinone marine natural products. Bioorg. Med. Chem. 2004, 13 (2), 387-395.
16. Pauil, D. K.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and analysis of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. 1989, 81, 1088-1092.
17. White, J. D.; Yager, K. M.; Yakura, T. Synthetic studies of the pyrroloquinoline nucleus of the makaluvamine alkaloids. Synthesis of the topoisomerase II inhibitor makaluvamine D. J. Am. Chem. Soc. 1994, 116, 1831-1838.
18. Kampouris, E. M. Preparation of nitroquinols and their methyl ethers and benzenesulfonyl derivatives. J. Chem. Soc. C 1967, (13), 1235-1238.
19. Phillips, M. A. The formation of 2-substituted benzimidazoles. J. Chem. Soc. 1928, 2393-2399.
20. Zimmer, H.; Lankin, D. C.; Horgan, S. W. Oxidations with potassium nitrosodisulfonate (Fremy's radical). The Teuber reaction. Chem. Rev. 1971, 71, 229-246.
21. Boyd, M. R. Status of the NCI Preclinical Antitumor Drug Discovery Screen. In Principles and Practices of Oncology (PPO updates), 3rd ed.; DeVita, V. T., Hellman, S., Rosenberg, S. A., Eds.; J. B. Lippincott: Phildelphia, PA, 1989; Vol. 3, pp 1-12.
22. Boyd, M. R.; Pauli, K. D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 1995, 34, 91-109.
23. Xing, C.; Skibo, E. B.; Dorr, R. T. Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: Structure-activity relationships for cytotoxicity and antitumor activity. J. Med. Chem. 2001, 44, 3545-3562.
24. Beneteau, V.; Pierre, A.; Pfeiffer, B.; Renard, P.; Besson, T. Synthesis and antiproliferative evaluation of 7-aminosubstituted pyrroloiminoquinone derivatives. Bioorg. Med. Chem. Lett. 2000, 10 (19), 2231-2234.
25. Sausville, E. A.; Zaharevitz, D.; Gussio, R.; Meijer, L.; Louarn-Leost, M.; Kunick, C.; Schultz, R.; Lahusen, T.; Headlee, D.; Stinson, S.; Arbuck, S. G.; Senderowicz, A. Cyclin-dependent kinases: Initial approaches to exploit a novel therapeutic target. Pharmacol. Ther. 1999, 82 (2-3), 285-292.
26. Ross, D. T.; Scherf, U.; Eisen, M. B.; Perou, C. M.; Rees, C.; Spellman, P.; Iyer, V.; Jeffrey, S. S.; Van De Rijn, M.; Waltham, M.; Pergamenschikov, A.; Lee, J. C. E.; Lashkari, D.; Shalon, D.; Myers, T. G.; Weinstein, J. N.; Botstein, D.; Brown, P. O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 2000, 24 (3), 227-235.
27. Ross, D. D.; Doyle, L. A. Mining our ABCs: Pharmacogenomic approach for evaluating transporter function in cancer drug resistance. Cancer Cell 2004, 6 (2), 105-107.
28. Chan, S.-L.; Yu, V. C. Proteins of the Bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities. Clin. Exp. Pharmacol. Physiol. 2004, 31 (3), 119-128.
29. Harada, H.; Grant, S. Apoptosis regulators. Rev. Clin. Exp. Hematol. 2003, 7 (2), 117-138.
30. Motoyama, A. B.; Hynes, N. E. BAD: A good therapeutic target? Breast Cancer Res. 2003, 5 (1), 27-30.
31. Hollingshead, M. G.; Alley, M. C.; Camalier, R. F.; Abbott, B. J.; Mayo, J. G.; Malspeis, L.; Grever, M. R. In vivo cultivation of tumor cell in hallow fibers. Life Sci. 1995, 57 (2), 131-141.
32. Hollingshead, M. G.; Plowman, J.; Alley, M.; Mayo, J.; Sausville, E. Relevance of Tumor Models in Anticancer Drug Development. In Contrib. Oncol.; Krager Verlag: Germany, 1999; pp 109-120.
33. Sedlacek, H. H.; Czech, J.; Naik, R.; Kaur, G.; Worland, P.; Losiewicz, M.; Parker, B.; Carlson, B.; Smith, A.; Senderowicz, A.;Sausville, E. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol. 1996, 9 (6), 1143-1168.
34. Dijoux, M-G.; Schnabel, P. C.; Hallock, Y. F.; Boswell, J. L.; Johnson, T. R.; Wilson, J. A.; Ireland, C. M.; van Soest, R.; Boyd, M. R.; Barrows, L. R.; Cardellina Ii, J. H. Antitumor activity and distribution of pyrroioiminoquinones in the sponge genus Zyzzya. 2005 13 (21), 6035-6044.
35. Strumberg, D.; Pommier, Y.; Pauli, K.; Jayaraman, M.; Nagafuji, P.; Cushman, M. Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. J. Med. Chem. 1999, 42, 446-457.